| The main expertise of the EPO-GmbH consists in the preclinical
testing of novel anticancer agents in animal experiments. EPO uses for that purpose different mouse and rat strains maintained in modern and licensed animal facilities.
A broad panel of syngeneic (mouse and rat origin) and xenogeneic tumour models are available.
EPO has established a variety of unique patient-derived xenografts (breast, colon, leukaemia, lung ovarian and sarcoma). The establishment of additional customer-submitted models can be
performed by EPO.
|
![]() |
Copyright © 2007 of EPO GmbH - All rights reserved. 03. Dezember 2008.